Changes in the use of erythropoiesis ‐stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes

ConclusionSubsequent to important regulatory and reimbursement ESA‐related actions, total ESA exposure among cancer patients receiving myelosuppressive chemotherapy declined substantially. Today, fewer patients receive ESA therapy, and among those treated, more are initiated at hemoglobin levels <10 g/dL and are exposed for a shorter duration, consistent with current product labeling.

Source: Pharmacoepidemiology and Drug Safety - August 1, 2017 Category: Drugs & Pharmacology Authors: Prasad L. Gawade, Jesse A. Berlin, David H. Henry, Dianne Tomita, Barry D. Brooks, Janet Franklin, Brian D. Bradbury, Cathy W. Critchlow Tags: ORIGINAL REPORT Source Type: research